By: Elisabeth Oehrlein, PhD, MS, Assistant Vice President, Research and Programs, National Health Council; and Tara Lavelle, PhD, Assistant Professor ...
Read moreGeneral Summary The Project Director will be a member of the Center for the Evaluation of Value and Risk in Health (CEVR), within the Institute for C...
Read moreCreation The Center for Enhanced Value Assessment (CEVA) headquartered within the Center for the Evaluation of Value and Risk in Health (CEVR) at Tuft...
Read moreDo LA, Synnott PG, Ma S, Ollendorf DA. Bridging the gap: aligning economic research with disease burden. BMJ Global Health 2021;6(6).
Neumann PJ, Ollendorf DA, Cohen JT. Value‐based drug pricing in the Biden era: Opportunities and prospects. Health Services Research 2021.
Ollendorf DA, Synnott PG, Neumann PJ. "External reference pricing: The drug-pricing reform America needs?," The Commonwealth Fund Issues Brief, May 27, 2021.
Chambers JD, Neumann PJ. "A next frontier in health care transparency: payer drug coverage policy," Health Affairs Blog, April 7, 2021.
Kim DD, Do LA, Daly AT, Wong JB, Chambers JD, Ollendorf DA, Neumann PJ. An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 Feb 23.
Olchanski N, van Klaveren D, Cohen JT, Wong JB, Ruthazer R, Kent DM. Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. Acta Diabetologica 2021.
Mulé CM, Lavelle TA, Sliwinski SK, Wong JB. Shared Decision-Making During Initial Diagnostic and Treatment Planning Visits for Children with Autism Spectrum Disorder. Journal of Developmental & Behavioral Pediatrics 2021.
Neumann PJ, Chambers JD. "Eroding progress on evidence and outcomes: CMS’s new proposed pathway for medical device coverage," Health Affairs Blog, December 2, 2020.
Basu A, Neumann PJ, Sullivan S. "International reference pricing: A lazy, misguided, bi-partisan plan to lower US drug prices," Health Affairs Blog, December 2, 2020.
Neumann PJ, Cohen JT, Kim DD, Ollendorf DA. Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic. Health Affairs 2020;40(1):53–61.
Lin, PJ, Cohen, JT, Neumann, PJ. Preparing the health‐care system to pay for new Alzheimer's drugs. Alzheimer's Dement. 2020; 1– 3.
Ma S, Kim DD, Cohen JT, Neumann PJ. "Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China," Value in Health (in press).
Kim, DD, Silver, MC, Kunst, N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974–2018. PharmacoEconomics 38, 1135–1145 (2020).
Xue F, Berklein F, Rane PB, Habib M, Lin PJ. "Patient characteristics and treatment patterns among Medicare beneficiaries initiating PCSK9 inhibitor therapy," Cardiovascular Drugs and Therapy, June 27, 2020.
Kim DD, Ollendorf DA, Neumann PJ, Fendrick M. "Crisis into opportunity: Can COVID-19 help set a path to improved health care efficiency?,"AJMC Commentary, June 17, 2020.
Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.
Meet the CEVR TeamOur comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.
The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.
View RegistryThe GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.
View RegistryThe Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.
View Database